Ownership and insider activity for Grifols, S.A. (GRFS): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions.
Price
| Price | $8.51 (closing price, November 2, 2026) |
| Market Cap | $7.2B |
| Exchange | NASDAQ |
| Country | ES |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 895.0M EUR | 886.5M EUR | 1.03B EUR | 832.9M EUR | 579.6M EUR | 655.5M EUR | 549.2M EUR | 529.6M EUR | 979.8M EUR | 824.6M EUR |
| Short-term Investments | 0 | 0 | 0 | 1.93B EUR | 10.9M EUR | 2.03B EUR | 31.0M EUR | 116.5M EUR | 21.2M EUR | 0 |
| Receivables | 528.5M EUR | 385.3M EUR | 401.6M EUR | 528.1M EUR | 383.2M EUR | 434.1M EUR | 774.2M EUR | 692.9M EUR | 1.08B EUR | 844.6M EUR |
| Inventory | 1.64B EUR | 1.63B EUR | 1.95B EUR | 2.63B EUR | 2.00B EUR | 2.26B EUR | 3.24B EUR | 3.48B EUR | 3.56B EUR | 3.29B EUR |
| Total Current Assets | 3.12B EUR | 2.95B EUR | 3.48B EUR | 6.02B EUR | 3.16B EUR | 5.51B EUR | 4.69B EUR | 6.13B EUR | 5.73B EUR | 5.07B EUR |
| Property, Plant & Equipment | 1.81B EUR | 1.76B EUR | 1.95B EUR | 3.21B EUR | 3.00B EUR | 3.34B EUR | 4.28B EUR | 4.19B EUR | 4.31B EUR | 4.05B EUR |
| Goodwill | 3.64B EUR | 4.59B EUR | 5.21B EUR | 6.18B EUR | 5.33B EUR | 6.23B EUR | 7.01B EUR | 6.80B EUR | 7.40B EUR | 6.83B EUR |
| Intangible Assets | 1.20B EUR | 1.27B EUR | 1.39B EUR | 1.61B EUR | 1.56B EUR | 1.00B EUR | 2.95B EUR | 1.21B EUR | 2.93B EUR | 2.73B EUR |
| Total Assets | 10.13B EUR | 10.92B EUR | 12.48B EUR | 17.45B EUR | 15.27B EUR | 19.23B EUR | 21.23B EUR | 20.99B EUR | 21.41B EUR | 19.75B EUR |
| Accounts Payable | 461.1M EUR | 423.1M EUR | 561.9M EUR | 653.2M EUR | 601.6M EUR | 629.0M EUR | 788.0M EUR | 823.0M EUR | 852.3M EUR | 840.6M EUR |
| Short-term Debt | 200.1M EUR | 129.1M EUR | 7.1M EUR | 358.7M EUR | 276.9M EUR | 2.35B EUR | 578.9M EUR | 916.5M EUR | 523.1M EUR | 385.8M EUR |
| Total Current Liabilities | 1.07B EUR | 978.0M EUR | 1.26B EUR | 1.53B EUR | 1.34B EUR | 3.47B EUR | 2.02B EUR | 2.33B EUR | 2.16B EUR | 2.02B EUR |
| Long-term Debt | 4.68B EUR | 5.87B EUR | 6.01B EUR | 6.84B EUR | 5.90B EUR | 6.94B EUR | 8.15B EUR | 8.99B EUR | 8.42B EUR | 7.39B EUR |
| Total Liabilities | 6.40B EUR | 7.29B EUR | 7.78B EUR | 9.75B EUR | 8.55B EUR | 11.92B EUR | 13.25B EUR | 13.48B EUR | 12.80B EUR | 12.13B EUR |
| Retained Earnings | 422.5M EUR | 539.7M EUR | 459.9M EUR | 0 | 618.5M EUR | 248.0M EUR | 0 | 79.4M EUR | 156.9M EUR | 0 |
| Total Equity | 3.72B EUR | 3.63B EUR | 4.23B EUR | 5.41B EUR | 5.11B EUR | 5.52B EUR | 5.65B EUR | 5.37B EUR | 5.88B EUR | 5.27B EUR |
| Total Debt | 4.89B EUR | 6.01B EUR | 6.03B EUR | 7.98B EUR | 6.91B EUR | 10.17B EUR | 9.75B EUR | 11.02B EUR | 10.09B EUR | 8.74B EUR |
| Net Debt | 3.99B EUR | 5.12B EUR | 5.00B EUR | 5.22B EUR | 6.32B EUR | 7.48B EUR | 9.17B EUR | 10.37B EUR | 9.08B EUR | 7.92B EUR |
| Working Capital | 2.05B EUR | 1.97B EUR | 2.23B EUR | 4.49B EUR | 1.83B EUR | 2.04B EUR | 2.67B EUR | 3.81B EUR | 3.57B EUR | 3.05B EUR |
Financial Health
| Debt / Equity | 1.54 |
| Current Ratio | 2.37 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 1.02 |
Profitability
| Return on Equity | 8.43% |
| Return on Invested Capital | 5.47% |
| Return on Assets | 2.25% |
| Gross Margin | 37.23% |
| Operating Margin | 16.66% |
| Net Margin | 6.09% |
Related companies: TECH · ADMA · MRVI · ABT · BDX · BIO · HAE
Explore sector: Healthcare · Drug Manufacturers - General
More sections of GRFS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks